And four other potential targets that could make sense for the beleaguered group.
Long-awaited results from the Herald study are a bust, and the data will likely deteriorate further.
With a Darpin antiviral for treating Covid-19 Molecular Partners hopes to follow Vir’s regulatory path.
Meanwhile, Ocugen hopes that Covaxin's India data will be enough for US approval.
The company might finally become an oncology player.
Though current vaccines show efficacy, work on next-generation iterations against the South Africa variant is under way.